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Abstract
End-stage Renal Disease (ESRD) is the terminal stage of Chronic Kidney Disease, where the function 
of the failing kidney must be substituted with Renal Replacement Therapy (RRT). There are two forms of 
RRT; Peritoneal Dialysis (PD) and Hemodialysis (HD. However, the issue of which method provide a better 
survival for patient remains an interesting topic to date. This paper aims to provide evidence on whether PD 
provides better survival compared to HD in a patient with ESRD. Systematic search was done using two 
databases; Pubmed® and Scopus®. Cohort studies were selected as appropriate study design to answer a 
prognosis question. Two restrospective cohorts and one prospective cohort study are relevant for this report. 
Two studies demonstrated survival advantage of PD over HD described by Relative Risk of Mortality of 0.398 
and 0.49. The last study showed worse survival of PD patients compared to HD (RR=1.82). The difference 
in survival in the last study may be attributed to the fact that patients undergoing PD has worse baseline 
characteristics. PDand HD bring about comparable survival in ESRD patients.
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Prognosis Dialisis Peritoneum Dibandingkan dengan Hemodialisis pada 
Pasien dengan Penyakit Ginjal Tingkat Akhir
Abstrak
Penyakit ginjal tingkat akhir merupakan stadium terminal dari Penyakit Ginjal Kronis (PGK), dimana 
fungsi ginjal harus disubstitusi oleh terapi pengganti ginjal. Terdapat dua pilihan terapi pengganti ginjal saat 
ini, yakni dialisis peritoneum dan hemodialisis (HD). Pemilihan tipe terapi pengganti ginjal bagi setiap pasien 
bergantung pada pertimbangan medis maupun non-medis. Namun demikian, tipe terapi mana yang dapat 
memberikan kesintasan terbaik pagi pasien masih menjadi topik perdebatan sampai saat ini. Laporan kasus 
berbasis bukti ini bertujuan menyajikan bukti pilihan terapi mana yang terbaik untuk kesintasan pasien dengan 
penyakit ginjal tingkat akhir. Terdapat dua penelitian retrospective cohort dan satu prospective cohort yang 
dikaji dalam laporan ini. Dua penelitian menyebutkan bahwa dialisis peritoneum memberikan kesintasan yang 
lebih  baik dibandingkan hemodialisis dengan masing-masing risiko relatif pada kematian sebesar 0,398 
dan 0,49). Penelitian ketiga menunjukkan kesintasan dialysis peritoneum yang lebih buruk dibandingkan 
hemodialisis dengan risiko relative 1.82. Perbedaan ini kemungkinan disebabkan karena perbedaan lini basis 
pasien yang mendapatkan terapi dialisis peritoneum. Dengan demikian, kesintasan pasien penyakit ginjal 
tingkat akhir yang mendapat terapi dialisis peritoneum dan hemodialis dapat dibandingkan.
Kata kunci: Penyakit ginjal tingkat akhir; dialisis peritoneum; hemodialisis, kesintasan
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Introduction
End-stage renal disease (ESRD) is the terminal 
stage of chronic kidney disease (CKD), where there 
is complete or almost complete failure for the kidney 
to work, measured by the gromerular filtration rate 
(GFR) of less than 15%. The number of patients 
with diabetes mellitus (DM) and end-stage renal 
disease (ESRD) and are being treated with renal 
replacement therapy (RRT/dialysis) is increasing 
dramatically. Across 46 developed and developing 
countries, it is estimated that RRT incidence rates 
ranges from 12 to 155 (median 130) per million 
population.1 
Although kidney transplantation remains the 
best treatment option for eligible patients with 
ESRD, rates of kidney donation have not kept pace 
with the number of cases, leading to an increase in 
the number of patients on waiting lists. Thus, most 
patients with ESRD, including those eligible for 
kidney transplantation, must select a type of dialysis 
for renal replacement therapy.2 Previous study in the 
US demonstrated that selection of peritoneal dialysis 
(PD) over hemodialysis (HD) was associated with 
patients younger age, white race, fewer comorbid 
conditions, and lower serum albumin as well as 
those who are  employed, married, and living with 
someone before the start of ESRD, and were more 
autonomous and better educated.3 Even though the 
use of dialysis is determined by both medical and 
non-medical factors, evaluating whether differences 
exist in the mortality outcomes of PD and HD is of 
considerable interest.4,5 
This evidence-based case report aims to 
address the question of whether PD provides better 
survival than HD in patients with ESRD.
Case Ilustration
 A female patient, 58 years old, complained of 
worsening fatique since 10 days before admission 
accompanied with flank pain, itchy skin, decreased 
urination without dysuria, or fever. Upon admission 
patient also complained of a diarrhea since a day 
before admission. Patient have had hypertension 
and DM since 14 years before admission, both 
were controlled with medication. On physical 
examination, patient was conscious, BP 
130/70mmHg, pulse 76x/min, respiratory rate 20x/
min, temperature 36oC, conjungtiva were anemic. 
Laboratory assessment showed anemia (Hb 8.7g/
dL), ureum 12.7; creatinin 227, and hyperkalemia 
(potassium 5.8). Patient was diagnosed with CKD 
Stage V, UTI, Type 2 DM, hypertension. Patient 
was hospitalized for CAPD installation.  
Clinical Question
Based on the case, the clinical question was 
formulated as follow: in patients with stage V CKD, 
does PD improve survival over HD?
Methods
The clinical question in this study is a prognosis 
question, therefore systematic reviews of cohort 
studies and cohort studies are the suitable study 
designs to answer this question.6  Evidences are 
searched from available databases i.e: Pubmed® 
and Scopus®. The keywords inputted are 
“Peritoneal Dialysis AND Hemodialysis AND End-
stage Renal Disease AND Survival”. Inclusion 
criteria are systematic reviews and cohorts by 
design, english texts, published between 2004-
2014, end stage (stage V) CKD patients going 
through PD or HD, survival or mortality as outcome. 
The exclusion criteria include are early stages of 
CKD, patients younger than 18 years of age, 
patients with prior renal transplantation.
Results
Pubmed and Scopus databases were used to 
find the evidence. Using predetermined keywords, 
526 and 416 manuscripts were found in Pubmed® 
and Scopus® respectively. The manuscripts were 
further selected by inclusion and exclusion criteria, 
resulting in 3 articles suitable for this EBCR.
Restrospective cohort study conducted by 
Rufino et al7 compared medium-term survival 
between 1469 patients with PD (173 patients) 
and HD (1296 patients) in Canary Islands, Spain. 
Among patients with PD, 62.4% were diabetics 
and among patients with HD, 44% were diabetics. 
Medium-term survival was defined as survival over 
the period of four years after the start of respective 
therapy by intention-to-treat analysis. The study 
analyzed survival of PD over HD among several 
subgroups, including DM status, age, gender 
and province of origin. The study utilizes the cox 
proportional regression model and estimated 
propensity score for survival to estimate the relative 
risks of mortality while on PD relative to HD. This 
study shows, the mortality risk was lower 61% for 
PD than for HD (RR= 0.398; p-value<0.005; 95% 
CI 0.237-0.669).
Choi et al. 8 conducted a nationwide prospective 
observational cohort study in Korean patients with 
ESRD on survival of PD over HD. A total of 1,060 
patients who were at least 20 years old and began 
treatment with maintenance dialysis due to ESRD 
from 31 centers affiliated with research center for 
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ESRD were enrolled from September 1, 2008 to 
June 30, 2011. Data on patients’ age, sex, height, 
weight, primary renal disease, and comorbid 
conditions, laboratory results, and dialysis 
information were analyzed using cox proportional 
hazard model to estimate the relative hazard 
ratio (HR) of mortality for PD compared to HD. 
The analysis used propensity matching to reduce 
selection bias and control for potential confounding 
factors (n=556).  PD has 51% lower risk of death 
than HD (HR= 0.49; p-value<0.05; 95%CI 0.25-
0.97) from day 90 to 30 months in the propensity-
matched population8.
Chang et al.9 in South Korea observed a better 
survival of HD in patients with DM compared to 
PD. This restrospective cohort study recruited 873 
subjects initiated on HD (69.3%) or PD (30.1%) on 
January 2000 to 30 June 2009 in Gachon University 
Gil Hospital, South Korea. The remaining subjects 
(0.6%) were excluded from analysis due to change 
of one modality to another during the time of study. 
All subjects were followed from the initiation of 
dialysis until the end of the study or death. The data 
were analyzed with multiple regression model and 
estimated propensity score (to reduce selection 
bias and control for potential confounding factors) 
with age, sex, cause of ESRD, medical history, and 
laboratory tests as covariates. Overall, HD provides 
survival advantage over PD. Mortality is higher in 
PD versus HD (HR=1.82; p-value<0.005; 95% CI 
1.23-2.69) The prevalence of DM was 53.5% in 
among HD patients and 57.1% in PD patients. The 
data was shown in hazard ratio (HR= 2.86, 95% 
CI= 1.73-4.74) using cox proportional analysis of 
the matched cohort (n=424).9
The three articles were further assessed using 
the critical appraisal sheet for prognosis study 
provided by Oxford CEBM (Table 1-3).10
Table 1. Validity of the Studies
Validity Rufino et al. 7 Choi et al.8 Chang et al.9
Was the defined, representative sample of patients assembled at a common 
point in the course of their disease?
  
Was patient follow-up sufficiently long and complete?   
Were objective outcome criteria applied in a “blind” fashion?   
If subgroups with different prognoses are identified, was there adjustment 
for important prognostic factors?
  
Table 2. Importance of the Studies
Importance Rufino et al. 7 Choi et al.8 Chang et al.9 
How likely are the outcomes over time?
RR (95% CI) of mortality
PD vs. HD RR=0.398 
(0.237-0.669)
PD vs. HD
RR= 0.49 (0.25-0.97)
PD vs. HD
RR= 1.82 (1.23-2.69)
How precise are the prognostic estimates? Precise  95% 
confidence interval 
less than 1
Not Precise  95% 
confidence interval 
less than 1, but close 
to 1 (0.97)s
Precise  95% confidence 
interval greater than 1
Table 3. Applicability of the Studies
Applicability Rufino et al. 7 Choi et al.8 Chang et al.9 
Is my patient so different to those in the study that the results 
cannot apply?
No No No
Will this evidence make a clinically important impact on my 
conclusions about what to offer to tell my patients
  
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Discussion
Failing kidney in ESRD has a great need 
for RRT. Generally, RRT can be applied either 
intermittently or continuously using extracorporeal 
method (HD) or paracorporeal method (PD). 
The method of choice varies greatly depending 
on patient and disease characteristics such as 
hemodynamic stability and other organ failures, as 
well as cost.4
Basically, RRT employs two physiologies 
for solute and fluid movement. Both methods 
require sequestration of blood on one side of a 
semipermeable membrane. Firstly, in dialysis, 
solute move down its concentration gradient and 
must be of appropriate size and charge to pass 
the semipermeable membrane. By passing fluid 
across the membrane countercurrent to blood 
flow, equilibration of plasma and dialysate solute 
concentrations occur. This process may remove or 
add solute to the plasma water space depending 
upon the relative concentrations in dialysate and 
plasma. Water will also move along a gradient, in 
this case the osmolar or osmotic gradient. Diffusive 
clearance is more effective at removal of small 
solute, such as serum ions and urea, than for larger 
solute.
Secondly, convective clearance (hemofiltration 
or ultrafiltration) utilizes a pressure gradient rather 
than concentration gradient and has its main 
effect on water movement with solute movement 
in conjunction with water. The transmembrane 
pressure difference is increased as needed 
to move water through the membrane down a 
pressure gradient. This bulk flow of plasma water 
drags solute with it (convective mass transfer) in 
the formation of ultrafiltrate. Small solute removal is 
nearly the same as with diffusion, but fluid removal 
is far superior with convective clearance.11 In these 
respects, blood may be passed through tubing and 
across artificial membranes (HD or hemofiltration), 
or dialysate may be instilled adjacent to the 
peritoneal membrane. HD remains the mainstay 
therapy for ESRD, according to a survey in 2005 
where 89% of 1.3 million patients receiving RRT 
worldwide received HD while the other 11% 
receiving PD.12 Among diabetic population, the 
average annual incidence of ESRD was 12 times 
greater compared to those of non-diabetic controls 
(130 cases vs 11 cases).13
Among the three studies appraised in this 
report, the first study by Rufino et al.7 observed 
survival advantages of PD over HD in both short 
and medium term, independent of age, gender, 
and diabetic status. Limitations in this study lie 
on the lack of randomization due to the nature of 
a restrospective cohort study and are limited to 
Spanish population in certain area.
Choi et al. 8 exhibits superior survival of PD 
compared to HD from day 90 to 30 months period 
(HR=0.49; p-value<0.05; 95% CI 0.25-0.97). This 
study is a prospective, nationwide cohort study in 
South Korea. Critics may stipulate that the better 
survival of PD in ESRD patients in this study is 
attributed to the fact that PD patients had better 
predialysis conditions than HD patients (younger 
age, lower BMI, better baseline hemoglobin level, and 
lower rate of comorbidities). However, the authors 
in this study reasoned that they used propensity 
matching score to control such confounding factors 
in order to overcome the limitation of non-random 
allocation to dialysis modality. 
Contrary to the first two studies, the third 
study by Chang et al.9 demonstrated that HD lead 
to better survival in ESRD patients (RR=1.82; 
p-value<0.005; 95% CI 1.23-2.69). The authors 
proposed several reasons for the higher mortality 
of PD patients, including the characteristics of PD 
patients that have higher serum lipoprotein (a) and 
hyperlipidemia that may accelerate atherosclerosis. 
In addition, inadequate dialysis and fluid overload 
may occur because the residual renal function and 
ultrafiltration capacity of the peritoneal membrane 
in PD patients decrease overtime. Limitations in 
this study include modest sample size that resulted 
in limitation of power and reduced generalizability 
due to a single-center experience.
This evidence-based case report provides 
comparable result on the survival of ESRD patients 
undergoing PD compared to HD. The results of 
this report can be applied to daily clinical practice. 
As illustrated, our patient, a 58 years-old female 
with stage V CKD. Chronic ambulatory peritoneal 
dialysis as a type of PD is an appropriate choice 
for this patient. However, bearing in mind that our 
patient has type 2  DM as the underlying condition 
of her ESRD, further evidence must be reviewed.
Type 2 DM is the most common subgroup of the 
metabolic disease characterized by hyperglycemia 
that result from defect of insulin resistance 
and relative insulin deficiency. The chronic 
hyperglycemia in DM is the notorious culprit that 
causes long term damage, dysfunction, and failure 
or different organs over the years, especially the 
kidneys, eyes, nerves, heart, and blood vessels.14
The kidney complication of DM is known 
as diabetic nephropathy, a clinical syndrome 
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characterized by albuminuria, hypertension, and 
progressive renal insufficiency. The earliest clinical 
manifestation is the presence of small but abnormal 
levels of albumin in the urine (microalbuminuria). 
Microalbuminuria generally precedes overt 
proteinuria by 5-10 years. Once proteinuria is 
detected, renal function gradually deteriorates 
over 10-15 years, leading to ESRD . DM may exist 
either as the underlying disease of ESRD or as a 
comorbid condition of ESRD. 
ESRD secondary to diabetic nephropathy 
requiring RRT is the most serious complications of 
DM above hypertension, gromerulonephritis, and 
cystic kidney. The United States Renal Data System 
in 2005 reported that the incidence of ESRD was 
40.5% with DM. In Germany and Australia, 36% 
and 22% dialysis patients have ESRD as a result 
of diabetic nephropathy. In Iran, 25.2% of dialysis 
patients are reported to have ESRD secondary to 
diabetic nephropathy.15
The prognosis of patients who have DM and are 
receiving RRT has improved significantly. However, 
survival and medical rehabilitation rate continue 
to be significantly worse than that of non-diabetic 
patients. This is mainly attributed to preexisting 
severely compromised cardiovascular conditions. 
The most common RRT modality in patients 
with DM is HD, but theoretically, it gives rise to a 
number of clinical problems, in particular difficulties 
in the management of the vascular access and 
high frequency of intradialytic hypotension. On the 
other hand, patients who have DM and are on PD 
have to face a progressive increase in peritoneal 
permeability, loss of ultrafiltration, and peritoneal 
fibrosis, all phenomena being accelerated in patients 
with DM and ultimately leading to an increased 
technique failure.16 
In our patient, a female 58 years of age with 
ESRD and 13 years history of DM, awaiting for 
CAPD installation, PD may provide a better survival 
as shown by a study by Serafinceanu et al.17 The 
study analyses 788 diabetic ESRD patients initiated 
on HD or PD between January 1995 to December 
2005 in the Dialysis Center of NIDNMD Paulescu, 
Bucharest. All patients were followed up for at least 
12 weeks or until their death. A total of 508 patients 
were initiated on HD where 199 (39.17%) of those 
patients were deceased within the first 12 weeks 
after initiation. There are 280 patients that received 
PD among the samples, 38 (13.57 %) of which were 
deceased within the first 12 weeks of initiation. The 
survival, or in this case, mortality was expressed 
in Relative Risk (RR= 2.89, 95%; p-value <0.0001 
CI= 2.11-3.95) of HD over PD in diabetic ESRD 
patients. This relationship remains significant 
across both sexes, albeit stronger in males 
(RR=4.54; p-value <0.0001; 95% CI 2.67-7.67) 
than in females (RR=1.89; p-value<0.0001, 95% 
CI 1.29-2.79). The authors in this study stipulated 
that this is the case due to the fact that HD is only 
used as the rescue therapy method in their center 
for late initiation of dialysis or late referral and thus 
associated with worse prognosis.17 
Furthermore, Rufino et al.7 also supports 
the survival advantage of PD versus HD in 
diabetic ESRD patients. In accordance with the 
two mentioned studies, Choi et al.8 study also 
demonstrates the superiority of PD over HD in 
diabetic patients younger than 65 years of age.
Nevertheless, for the long term, DM must be 
properly controlled and its complications closely 
monitored to ensure highest quality of life in this 
patient. Prevention of peripheral arterial disease 
is also necessary to preserve vasculature for 
when PD fails and vascular access needed for 
“rescue” hemodialysis. Furthermore, it would be 
interesting to investigate the survival of PD and HD 
in Indonesian diabetic ESRD population in relation 
with the relatively high infection in this country.
Conclusion
In ESRD patients where RRT is necessary, 
studies showed comparable results on the survival 
advantage of PD versus HD. More studies that 
include multicenter and large number of subjects 
are needed to provide further evidence for this 
issue, especially with DM as the cause of ESRD. 
Acknowledgement
The author would like to extend her gratitude 
to dr. Irsan Hasan SpPD-KGEH, who has patiently 
guided the author throughout the writing process of 
this evidence-based case report.
References
1. Caskey FJ, Kremer A, Elliot RF, Stel VS, Covic 
A, Cusumano A, et al. Global variation in renal 
replacement therapy for end-stage renal disease. 
Nephrol Dial Transplant. 2011;0:1-7.
2. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, 
Levey AS, et al. Comparing the risk for death with 
peritoneal dialysis and hemodialysis in a national 
cohort of patients with chronic kidney disease. 
Annals of Internal Medicine. 2005;143(3):174-83.
3. Stack A. Determinants of modality selection among 
incident US dialysis patients: results from a national 
study. Ann Intern Med. 2005;143:174-83.
Meutia Ayuputeri  
62
4. Vonesh E, Snyder J, Foley R, Collins A. Mortality 
studies comparing peritoneal dialysis and 
hemodialysis: what do they tell us? Kidney 
International. 2006;70:s3-11.
5. Keshaviah P, Collins AJ, Ma JZ, Churchill DN, Thorpe 
KE. Survival comparison between hemodialysis 
and peritoneal dialysis based on matched doses of 
delivered therapy. Journal of the American Society 
of Nephrology. 2001;13(suppl1):S48-52.
6. Straus SE, Glasziou P, Richardson WS, Haynes 
RB. Evidence-based medicine: how to practice and 
teach it. China: Churchill Livingstone Elsevier; 2011.
7.   Rufino HJM, García C, Vega N, Macía M, 
Hernández D, Rodríguez A, et al. Current peritoneal 
dialysis compared with haemodialysis: medium-
term survival analysis of incident dialysis patients 
in the canary Islands in recent years. Nefrologia. 
2011;31(2):174-84.
8. Choi JY, Jang HM, Park J, Kim YS, Kang S-W, 
Yang CW, et al. Survival advantage of peritoneal 
dialysis relative to hemodialysis in the early period of 
incident dialysis patients: a nationwide prospective 
propensity-matched study in Korea. PLOS one. 
2013;8(12):331-41.
9. Chang JH, Sung JY, Ahn SY, Ko K-P, Ro H, Jung JY, et 
al. Hemodialysis leads to better survival in patients with 
diabetes or high comorbidity, compared to peritoneal 
dialysis. Tohoku J Exp Med. 2013;229:271-7.
10. Heneghan C, Badenoch D. Evidence-based 
medicine toolkit. London: BMJ Books; 2002.
11. Fleming GM. Renal replacement therapy: 
past, present, and future. Organogenesis. 
2011;7(1):2-12.
12. Grassman A, Gioberge S, Moeller S, Brown G. 
ESRD patients in 2004: global overview of patient 
numbers, treatment modalities and associated 
trends. Nephrol Dial Transplant. 2005;20:2587-93.
13. Lok C, Oliver M, Rothwell D, Hux J. The 
growing volume of diabetes-related dialysis: a 
population based study. Nephrol Dial Transplant. 
2004;19(12):3098-103.
14. Diagnosis and classification of diabetes mellitus. 
Diabetes Care. 2010;22(Suppl 1):s62-9.
15. Broumand B. Diabetes: changing the fate of diabetics 
in the dialysis unit. Blood Purif. 2007;25:39-47.
16. Locatelli F, Pozzoni P, Del Vecchio L. Renal 
replacement therapy in patients with diabetes and 
end-stage renal disease. Journal of the American 
Society of Nephrology. 2004;15(suppl 1):S25-9.
17. Serafinceanu C, Neculaescu C, cimponeriu D, 
Timar R, Covic A. Impact of gender and dialysis 
modality on early mortality risk in diabetic ESRD 
patients: data from a large single center cohort. Int 
Urol Nephrol. 2014;46(3):607-14. 
